Eisai Co., Ltd. has introduced plans to current vital findings from its Alzheimer’s illness analysis, together with knowledge on its anti-amyloid beta (Aβ) protofibril antibody, lecanemab, on the Alzheimer’s Association International Conference 2026 (AAIC) in London. The firm will showcase 52 abstracts throughout its Alzheimer’s illness portfolio, highlighting developments in remedy and intervention methods.
The displays will embody a Developing Topics Session and a Featured Research Session on lecanemab, that includes a number of oral displays and posters. Eisai may also maintain a symposium on early intervention in Alzheimer’s illness, emphasizing the significance of well timed remedy.
A key focus of the Developing Topics Session would be the subcutaneous formulation of lecanemab, exploring scientific proof and real-world affected person experiences. The Featured Research Session will current knowledge from the LEADER examine, evaluating real-world use of lecanemab in various U.S. scientific settings three years post-approval. This consists of findings on upkeep dosing with intravenous remedy and subcutaneous administration at residence.
Additional displays will cowl the Phase 3 AHEAD 3-45 examine in preclinical Alzheimer’s illness, offering updates on participant retention and engagement. There may also be discussions on a Phase 2 trial of etalanetug, an anti-MTBR tau antibody, together with lecanemab, inspecting its results on tau pathology.
Lynn D. Kramer, M.D., FAAN, Chief Clinical Officer of Deep Human Biology Learning at Eisai, highlighted the corporate’s dedication to advancing Alzheimer’s care by a complete knowledge set spanning the illness continuum and a number of therapeutic targets.
Other classes will delve into varied elements of lecanemab’s scientific software, corresponding to sex-based outcomes, racial and ethnic variations in biomarkers, and the financial affect of delayed Alzheimer’s development. The convention may also function displays on etalanetug, exploring its potential as a disease-modifying remedy for tauopathies.
Eisai’s collaboration with Biogen and BioArctic has been pivotal within the improvement and commercialization of lecanemab, which is accepted in 53 international locations. The firm’s ongoing scientific research intention to additional improve understanding and remedy of Alzheimer’s illness, with a give attention to early intervention and patient-centered care.